Founded with the mission to revolutionize dermatological treatments, SkinJect focuses on developing innovative drug delivery systems specifically for non-melanoma skin cancers, such as basal and squamous cell carcinoma. Their primary product, the SkinJect Patch, offers a simple and effective regimen to address these prevalent skin cancers, which affect a significant portion of the aging population. By targeting an unmet clinical need, SkinJect aims to improve patient outcomes and streamline treatment processes in dermatology.
SkinJect has garnered attention through its collaborations with academic institutions and industry experts. The company has achieved significant milestones in clinical trials, demonstrating the efficacy and safety of its patch technology. With backing from notable investors and a dedicated management team, SkinJect is poised to make a substantial impact on the treatment landscape for non-melanoma skin cancers, offering a less invasive and more accessible option for patients worldwide.
